Cellectar Biosciences Secures $6 Million in Public Offering
FLORHAM PARK, N.J. — Cellectar Biosciences, Inc. (Nasdaq: CLRB), a leading clinical biopharmaceutical company, has announced significant pricing details regarding a new underwritten public offering, which is expected to generate around $6 million in gross proceeds, before deducting expenses and underwriting fees.
Offering Structure and Units
The offering includes 865,000 Class A Units, where each unit comprises one share of common stock and one common warrant designed to purchase one additional share of common stock. Alongside, 335,000 Class B Units are also part of this offering, which includes one pre-funded warrant for a share of common stock and an accompanying common warrant. The pricing for each Class A Unit is set at $5.00, while each Class B Unit is priced at approximately $4.99999, collectively referred to as the Offering.
Warrants and Pricing Details
The common warrants are priced at $5.25 per share, are immediately exercisable upon issuance, and will be valid for five years following the issuance date. The involvement of Ladenburg Thalmann & Co. Inc. as the sole bookrunning manager highlights the professionalism and the strategic partnership aimed at ensuring the success of this offering.
Anticipated Closing and Over-Allotment Option
The expected date for the closing of the Offering is July 2, 2025, contingent upon fulfilling standard closing conditions. Additionally, the underwriter has been granted a 45-day option to acquire up to 180,000 extra shares or common warrants to address any over-allotments.
Strategic Use of Funds
With the anticipated gross proceeds of approximately $6 million, Cellectar plans to allocate the net proceeds toward corporate purposes, especially to bolster working capital, cover operating expenses, and initiate a Phase 1b clinical trial for its promising compound, CLR 121125 (CLR 125), targeting triple-negative breast cancer.
Importance of Effective Registration
This public offering is authorized under a registration statement on Form S-1, declared effective by the SEC. A preliminary prospectus associated with this offering has been filed, ensuring transparency and regulatory compliance in the process.
Company Overview
Cellectar Biosciences is focused on innovating treatments in the biopharmaceutical sector, particularly for cancer. Utilizing their proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform, Cellectar endeavors to create next-generation cancer therapies that emphasize superior efficacy and minimal off-target side effects. Through strategic collaborations and intensive research, the company aims to advance its drug candidates effectively.
Contact Information
For further inquiries about this announcement or the company, investors may reach out to Anne Marie Fields at Precision AQ by calling 212-362-1200 or emailing annemarie.fields@precisionaq.com.
Frequently Asked Questions
What is the goal of Cellectar Biosciences' recent offering?
The primary aim is to raise $6 million to support general corporate purposes, including research and clinical trials for new cancer treatments.
How are the Class A and Class B units structured?
Class A units consist of one share of common stock and one common warrant, while Class B units include a pre-funded warrant for one share of common stock and a common warrant.
What is the anticipated closing date for this offering?
The closing of the offering is expected to occur around July 2, 2025, subject to meeting standard conditions.
How will the company utilize proceeds from the offering?
The proceeds will primarily be used for working capital, operational expenses, and to initiate a clinical trial for CLR 121125 in triple-negative breast cancer.
Who is overseeing the offering process?
Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager for the offering, providing expertise and management in this financial endeavor.
